Medicines Management Programme Update
|
|
- Catherine Greene
- 6 years ago
- Views:
Transcription
1 Medicines Management Programme Update Sarah Clarke Chief II Pharmacist and Programme Manager Medicines Management Programme (MMP)
2 Millions ( ) The Medicines Management Programme (MMP) The Medicines Management Programme (MMP) was established in January Aim - sustained national leadership relating to Safe Effective Cost effective prescribing
3 Health Act 2013 Interchangeable medicinal products Reference Pricing Establishment of reimbursement list ( Executive may attach conditions to supply of listed items in the interests of one or more of the following: a) Patient safety b) Cost-effectiveness c) Maximise appropriate use of listed item d) Appropriately applying the resources available to the Executive
4 So what is being done? HTA to the patented side of the market % expenditure Reduce INN Generic 5% Branded Generic 7% Brand - off patent 10% expenditure in the off patent side of the market Prior to reimbursement approval For continued reimbursement approval Patent Brand 78% Generic Prescribing Biosimilars Hospital prescribing
5 Statins - SIMVASTATIN PPI - LANSOPRAZOLE ACE inhibitor - RAMIPRIL ARB - CANDESARTAN SSRI - CITALOPRAM SNRI - VENLAFAXINE OAC - WARFARIN (NOAC: APIXABAN) Antimuscarinics - TOLTERODINE SR
6 Most frequently prescribed medicines Acetylsalicylic Acid Atorvastatin Levothyroxine sodium Paracetamol Bisoprolol Calcium combinations Salbutamol (Inhaled) Esomeprazole Amlodipine Rosuvastatin
7 Statins April 2013 Simvastatin is recommended as the statin of first choice Over 310,000 patients receive a statin each month Approx 4.2 million statin prescriptions issued/annum Total expenditure exceeds 50 million/annum The calculated ingredient cost per prescription item for simvastatin remains the lowest in the therapeutic class
8 Proton pump inhibitors (PPIs ) April 2013 Lansoprazole is recommended as the PPI of first choice Over 265,000 patients receive a PPI each month Approx. 3.6 million PPI prescriptions issued/annum Total expenditure exceeds 55 million/annum Esomeprazole is one of the most expensive PPIs and accounts for over 32% of all PPI prescriptions
9 Inhaled medicines for Asthma and COPD There are over 50 licensed inhalers for asthma and over 25 licensed inhalers for COPD Expenditure on inhalers for asthma and COPD is approx. 98 million per annum ( 86 million GMS & 12 million DPS ). It is estimated that COPD accounts for 84% of this expenditure ( 82 million/annum )
10 Salmeterol + fluticasone (Seretide ) [34%] Tiotropium (Spiriva) [19%] Formoterol + budesonide (Symbicort ) [17.5%] Salbutamol [10%]
11 ICS and LABA inhalers for Asthma & COPD 50 million on ICS and LABA combination inhalers 44 million GMS 2.4 million/month Seretide (GMS only) 1.3 million/month Symbicort (GMS only) New products in this group including hybrid ( generic ) inhalers offer opportunity to reduce expenditure The Symbicort equivalent Bufomix (budesonide 320 µg + formoterol 9 µg) is 35% cheaper than Symbicort [ 42% cheaper than Seretide ]
12
13 Most expensive medicines What are we doing? Adalimumab Biosimilars, hospital engagement Clinical nutritional products Primary Care review underway Etanercept Biosimilars, e-authorisation Atorvastatin Preferred Drug Initiative Salmeterol + other drugs for OAD Prescribing and Cost Guidance Formoterol + other drugs for OAD Prescribing and Cost Guidance Tiotropium Prescribing and Cost Guidance Esomeprazole Preferred Drug Initiative Pregabalin Review underway post HTA
14 Non-Vitamin K oral anticoagulants (NOACs) Oral Methotrexate Preferred antibiotics in Primary Care Valproate project underway Available on:
15 Non Vitamin K Oral Anti-Coagulants (NOAC s) Apixaban (Eliquis ) Rivaroxaban (Xarelto ) Edoxaban (Lixiana ) Dabigatran (Pradaxa )
16 Patients 40,000 35,000 Total number of patients on anticoagulants under the GMS & DP schemes from January January ,722 30,000 25,000 Warfarin: 26,296 Dabigatran Rivaroxaban Warfarin Apixaban Edoxaban 20,000 15,000 10,000 5,000 0 Rivaroxaban Apixaban Dabigatran Edoxaban
17 1,200,000 Total expenditure on anticoagulants under the GMS & DP Schemes from January November ,000, , , ,000 Dabigatran Rivaroxaban Warfarin Apixaban Edoxaban 200,000 0
18 0% 0% 9% 4% Dabigatran Rivaroxaban Warfarin Apixaban 87% Edoxaban Proportion of patients on anticoagulation January % 0% 9% 26% Dabigatran Rivaroxaban Warfarin 49% Apixaban Edoxaban Proportion of patients on anticoagulation January 2016
19
20
21
22 Eculizumab (Soliris ) Paroxysmal Nocternal Haemoglobinuria(PNH) Atypical Haemolytic Uraemic Syndrome (ahus) 430,000+/patient/year Clinical review of applications for centralised reimbursement and outcome follow-up Ongoing follow up for clinical information
23 Jan-12 Mar-12 May-12 Jul-12 Sep-12 Nov-12 Jan-13 Mar-13 May-13 Jul-13 Sep-13 Nov-13 Jan-14 Mar-14 May-14 Jul-14 Sep-14 Nov-14 Jan-15 Mar-15 May-15 Jul-15 Sep-15 Nov-15 Versatis 5% Patch monitored by MMP 3,000,000 2,500,000 2,000,000 1,500,000 Total Expenditure on VERSATIS, GMS and DP NCPE HTA review Cost-effectiveness was not demonstrated 1,000, ,000 0 Price reduction was agreed MMP Prescribing Tips and Tools
24 Collaborations Rheumatology Diabetes Epilepsy/ Neurology HCAI/AMR Mental health
25 Blood Glucose Test Strips Total expenditure in 2014: 46.8million 26 individual test strips reimbursed International evidence suggests limited clinical benefit for type 2 patients not on insulin NCPD published new guidelines in 2015 MMP recommendations went live April 2016
26 Medicines Management Roadshow since 2014 GP and Nursing meetings
27 2016 and beyond Measurement of health outcomes in the clinical setting Use of fampridine for multiple sclerosis Use of eculizumab for PNH and ahus Failure of any technology to deliver satisfactory health outcomes should prompt a discussion around price reduction/disinvestment Oral nutritional supplements in the community setting Use of drugs such as pregabalin, versatis patch Supporting the use of biosimilars e.g. Adalimumab & Etanercept Hospital prescribing High Tech medicines e-authorisation processes (PAH, MS)
28
Medicines Management Programme Update
The Medicines Management Programme (MMP) Medicines Management Programme Update Michael Barry Clinical Lead HSE-Medicines Management Programme (MMP) www.hse.ie/yourmedicines What are our values? Ensuring
More informationNational Medicines Management Programme
National Medicines Management Programme Michael Barry 28 th November 2013 The Medicines Management Programme Multi-disciplinary Medicines Management Programme (MMP) headed by the National Medicines Information
More informationThe Sustainability of Irish Pharmaceutical Expenditure. Valerie Walshe Ph.D. Economist
The Sustainability of Irish Pharmaceutical Expenditure Valerie Walshe Ph.D. Economist valerie.walshe@hse.ie February 2015 Content Overview of Irish Health Services Community Drug Prescribing Trends Driving
More informationFeidhmeannacht na Seirbhíse Sláinte
Feidhmeannacht na Seirbhíse Sláinte Health Service Executive Feidhmeannacht na Seirbhíse Sláinte Seirbhís Aisíocaíochta Cúraim Phríomhúil Bealach amach 5 an M50 An Bóthar Thuaidh Fionnghlas Baile Átha
More informationMedicines Optimisation Annual Report Dr Emma Harris and Neil Hardy on behalf of the Medicines Management Team June 2016
Medicines Optimisation Annual Report 2015-2016 Dr Emma Harris and Neil Hardy on behalf of the Medicines Management Team June 2016 1 Clinical Objectives Improve the effective use of medicines Maximise health
More informationSwindon PCT/CCG - Cost based ASTRO-PU variance to the England average prescribing spend by month
Appendix x Swindon CCG Primary Care Prescribing Costs and Patient Outcomes Variance to the England average 105.00% Swindon PCT/CCG - Cost based ASTRO-PU variance to the England average prescribing spend
More informationThe Medicines Management Programme (MMP) update 3 rd National Medicines Forum RCPI 30 th April 2015 Michael Barry
The Medicines Management Programme (MMP) update 3 rd National Medicines Forum RCPI 30 th April 2015 Michael Barry The Medicines Management Programme (MMP) The Medicines Management Programme (MMP) was established
More informationEconomies in drug usage in the Irish healthcare setting
Economies in drug usage in the Irish healthcare setting Item type Authors Publisher Report Barry, Michael Department of Health and Children (DOHC) Downloaded 17-Jul-2018 01:57:58 Link to item http://hdl.handle.net/10147/66358
More informationThe Infection Control Doctor and Clostridium difficile infection. Dr David R Jenkins University Hospitals of Leicester NHS Trust, England
The Infection Control Doctor and Clostridium difficile infection Dr David R Jenkins University Hospitals of Leicester NHS Trust, England 250 200 150 100 50 0 Monthly cases of Clostridium difficile (UHL
More informationSummary of Lothian Joint Formulary Amendments
Summary of Lothian Joint Formulary Amendments The purpose of this summary is to detail the main changes to the LJF sections and provide additional information on the reasons for some of the changes. The
More informationPBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars
PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market PBS Update 2014-15 Growth in PBS spending was
More informationPrescribing & Medicines: Dispenser Payments and Prescription Cost Analysis
Publication Report Prescribing & Medicines: Dispenser Payments and Prescription Cost Analysis Financial Year 2016/17 Publication date 29 August 2017 An Official Statistics Publication for Scotland Contents
More informationREVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE
REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE ID NUMBER: 0a) Date of Collection / / 0b) Staff Code Instructions: This form should be completed during the participant s clinic visit. 1) Are you regularly
More informationLIGHTENING THE LOAD Reducing pill burden with appropriate discontinuation strategies
LIGHTENING THE LOAD Reducing pill burden with appropriate discontinuation strategies Disclaimer Statement This presentation is for educational purposes only. It is not intended as legal or professional
More informationGlobal Anticoagulants Market: Size, Trends & Forecasts ( ) April 2017
Global Anticoagulants Market: Size, Trends & Forecasts (2017-2021) April 2017 Global Anticoagulants Market Scope of the Report The report entitled Global Anticoagulants Market: Size, Trends & Forecasts
More informationResponsible Respiratory Prescribing
Responsible Respiratory Prescribing Dr Vincent Mak Consultant Physician in Respiratory Integrated Care Imperial College Healthcare and Central London Community Healthcare NHS Trust Respiratory Clinical
More informationPlavix eliquis and aspirin
Plavix eliquis and aspirin The Borg System is 100 % Plavix eliquis and aspirin 273 medications are known to interact with Plavix. Includes amlodipine, aspirin, Aspirin Low Strength ( aspirin ). Eliquis
More informationInclude patients: with a confirmed diagnosis of asthma who have been free of asthma symptoms for 3 months or more.
Corby Clinical Commissioning Group Kettering General Hospital NHS Trust Nene Clinical Commissioning Group rthampton General Hospital NHS Trust rthamptonshire Healthcare Foundation Trust Stepping down asthma
More informationWolverhampton CCG Medicines Optimisation Work plan 2017/18
Wolverhampton CCG Medicines Optimisation Work plan 2017/18 Wolverhampton Clinical Commissioning Group 1 Contents page Overall Outcomes 3 Patient Safety 3 Medicines Commissioning 4 QIPP 5 Areas of cost
More informationrequesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group
requesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group Canterbury and Coastal Clinical Consortium Group Medicine Management plans 2013/14
More informationCHARM ASTHMA TREATMENT GUIDELINE
NHS City and Hackney Prescribing Guidelines Adults ( 12 years of age) CHARM ASTHMA TREATMENT GUIDELINE Written by: Hetal Dhruve (Specialist Respiratory Pharmacist, City and Hackney CCG) Checked by: Prof
More informationForecasting and Monitoring Budgetary impact and medicines uptake
Forecasting and Monitoring Budgetary impact and medicines uptake Kate Jenkins and Paul Deslandes Welsh Analytical Prescribing Support Unit All Wales Therapeutics and Toxicology Centre WAPSU Remit Medicines
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationLincolnshire Prescribing and Clinical Effectiveness Bulletin
S Lincolnshire Prescribing and Clinical Effectiveness Bulletin Volume 12 No 10, November 2018 Optum in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationMeasuring and Evaluating Indicators of Appropriate Prescribing in Older. Populations
HRB PhD Scholar Division of Population Health Sciences RCSI Measuring and Evaluating Indicators of Appropriate Prescribing in Older Cost-Effective Proton Pump Populations Potential Strategies for more
More informationPosition within the Organisation
ASTHMA TREATMENT GUIDELINES Document Description Document Type Service Application Guidelines All healthcare professionals(hcps) caring for patients with asthma Version 4.0 Ratification date September
More informationEliquis and plavix combination therapy
Eliquis and plavix combination therapy ELIQUIS Dosing for Patients With NVAF. patients treated with aspirin or the combination of bleeding or completion of a course of therapy,. 9-11-2011 Thrombosis is
More informationNHS Dumfries & Galloway Triple therapy in COPD patients over 16 years
Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled
More informationPRESCRIPTION CLERK TRAINING EVENT SAFE, EFFECTIVE AND COST-EFFECTIVE PRESCRIBING PRESCRIBING INCENTIVE SCHEME
PRESCRIPTION CLERK TRAINING EVENT SAFE, EFFECTIVE AND COST-EFFECTIVE PRESCRIBING PRESCRIBING INCENTIVE SCHEME ACCESSING THE MEDICINES MANAGEMENT WEBSITE This we take you to a range of documents, policies
More informationInhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years & over
Manufacturer Submission To The National Institute for Health and Clinical Excellence By GlaxoSmithKline UK Inhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years
More informationpatient group direction
ASPIRIN v01 1/8 ASPIRIN PGD Details Version 1.0 Legal category P Staff grades Approved by Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)
More informationNot available 100/6mcg 2 BD formoterol (Fostair MDI) 100/6mcg 33
COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP FLUTICASONE FUROATE/VILANTEROL COMBINATION INHALER - ASTHMA Policy agreed by Vale of York CCG (date) Drug, Treatment, Device name Fluticasone
More informationASTRAZENECA v GLAXOSMITHKLINE
CASE AUTH/1986/4/07 ASTRAZENECA v GLAXOSMITHKLINE Symbicort and Seretide cost comparisons AstraZeneca complained about cost comparisons made by GlaxoSmithKline between AstraZeneca s Symbicort (budesonide/formoterol)
More informationTherapeutic options for adult patients unable to take solid oral dosage forms (Adapted from UKMi Q&A for use in Northern Ireland) Sep 2015
Therapeutic options for adult patients unable to take solid oral dosage forms (Adapted from UKMi Q&A 294.3 for use in Northern Ireland) Sep 2015 BNF 1.3.5 Proton pump inhibitors Lansoprazole orodispersible
More informationTricky Cases in Primary Care Anticoagulation in AF
Tricky Cases in Primary Care Anticoagulation in AF Dr John Wong GPwSI Cardiology & GP Principal Leatherhead Hospital Ashlea Medical Practice 54 year old F Case 1 PMH CREST Syndrome calcinosis finger tips
More informationAdult Summary flowchart for Asthma Switch and Step Down to ENHCCG preferred inhaler choices
ENHCCG Adult Asthma Switch and Step Down Algorithms - Approved by Hertfordshire Medicines Management Committee June 2016 Page 1 of 6 Adult Summary flowchart for Asthma Switch and Step Down to ENHCCG preferred
More informationSupplementary Online Content
Supplementary Online Content Caldeira D, Canastro M, Barra M, et al. Risk of substantial intraocular bleeding with novel oral anticoagulants: systematic review and meta-analysis. JAMA Ophthalmol. Published
More informationTools for Targeting High Risk Patients in Your Practice. Statement of Disclosure
Tools for Targeting High Risk Patients in Your Practice Joseph Vande Griend, PharmD, BCPS, CGP Assistant Professor, University of Colorado Departments of Clinical Pharmacy and Family Medicine Skaggs School
More informationAsthma Treatment Guideline for Adults (aged 17 and over)
Asthma Treatment Guideline for Adults (aged 17 and over) Sharon Andrew MLCSU January 2019 (Review date 0 January 2022) VERSION CONTROL. Please access via the LMMG website to ensure that the correct version
More informationGLORIA -AF REGISTRY PROGRAMME
GLORIA -AF REGISTRY PROGRAMME EXECUTIVE SUMMARY The approval of novel oral anticoagulants has changed prescribing patterns for stroke prevention in atrial fibrillation (AF) worldwide. 1 There is a need
More informationTreatments for stroke prevention in Atrial Fibrillation as recommended by the Canadian Cardiovascular Society
Treatments for stroke prevention in Atrial Fibrillation as recommended by the Canadian Cardiovascular Society Coumadin (Warfarin) Does this medication need ongoing monitoring of blood clotting times? Yes.
More informationReimbursement of Lidocaine 5% Plasters (Versatis ) effective 1 st September 2017
Feidhmeannacht na Seirbhíse Sláinte, Seirbhís Aisíocaíochta Cúraim Phríomhúil Bealach amach 5 an M50, An Bóthar Thuaidh, Fionnghlas Baile Átha Cliath 11, D11 XKF3 Guthán: (01) 864 7100 Facs: (01) 834 3589
More informationWhy Asthma Still Kills The National Review of Asthma Deaths (NRAD)
APPROVED FINAL VERSION NHS Protect Why Asthma Still Kills The National Review of Asthma Deaths (NRAD) Summary of Recommendations for GP Practices and Community Pharmacies Author: Anne Henry Contact: anne.henry@nhs.net
More informationMedications for Treating Stroke
Medications for Treating Stroke Subject Expert Sonny Kupniewski, PharmD, BCPS Swedish Medical Center Englewood, CO 2 Objectives Medications used to prevent stroke Prevention of strokes in patients with
More informationAnticoagulatie en de oudere patiënt: Terughoudenheid gerechtvaardigd of niet?
Anticoagulatie en de oudere patiënt: Terughoudenheid gerechtvaardigd of niet? 16/06/2018 apr. Julie Hias Satellite symposium supported by the Alliance BMS/Pfizer 432BE18PR03459/ 180570 (Date of Preparation:
More informationResponsible Respiratory Prescribing
Responsible Respiratory Prescribing Dr Vincent Mak Consultant Physician in Respiratory Integrated Care Imperial College Healthcare and Central London Community Healthcare NHS Trust NHS England (London)
More informationChapter 2 - Cardiovascular System. Primary Care Prescribing Formulary - Preferred Drug Choices
Chapter 2 - Cardiovascular System Primary Care Prescribing Formulary - Preferred Drug Choices Drug group Drug choice Comments/notes Cardiac glycosides Thiazide diuretics Loop diuretics Aldosterone antagonist
More informationMAXIMUM ALLOWABLE COST POLICY CHANGES DECEMBER 5, 2016 QUESTIONS AND ANSWERS
MAXIMUM ALLOWABLE COST POLICY CHANGES DECEMBER 5, 2016 QUESTIONS AND ANSWERS The November 22, 2016 Mid-Year Financial Report referred to changes to drug coverage under the Saskatchewan Drug Plan. What
More informationBack to Basics: The Basics of Medication Monitoring
DIAMOND PHARMACY SERVICES Back to Basics: The Basics of Medication Monitoring Presented by: Dr. Deborah Milito, Pharm. D., CGP. Director of Clinical and Consultant Services Skilled Division Annual Educational
More informationGlossary of Medications
CLPNA Medications Administration Module Glossary of Medications Acetaminophen. Acetaminophen is a non-opioid analgesic used to manage mild pain and fever. Acetylsalicylic acid. Acetylsalicylic acid is
More informationLidocaine 5% Medicated Plaster (Versatis )
Medicines Management Programme Lidocaine 5% Medicated Plaster (Versatis ) Prescribing and Cost Guidance Table of Contents 1. Background... 2 2. Purpose... 2 3. Definitions... 3 4. Mode of action... 3 5.
More informationThe era of NOACs. (non-vitamin K oral anticoagulants) in Clinical Pharmacy : Patrick Tilleul
The era of NOACs (non-vitamin K oral anticoagulants) in Clinical Pharmacy : Patrick Tilleul Head Pharmacist, Pitié Salpêtrière hospital Associate professor Paris Sorbonne University Disclosure Patrick
More informationGuide to the Modernized Reference Drug Program
Guide to the Modernized Reference Drug Program For prescribers and pharmacists Medical Beneficiary and Pharmaceutical Services Division June 1, 2016 Contents 1 Introduction 1 2 About this Guide 2 3 About
More informationrequesting information regarding atrial fibrillation in NHS Ashford Clinical Commissioning Group
October 2015 Our Ref: FOI.15.ASH0149 requesting information regarding atrial fibrillation in NHS Ashford Clinical Commissioning Group Original Request Survey attached. Question 1: Between 1 July 2014 and
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE December 2014 Review Date: December 2017 Bulletin 206 : DuoResp Spiromax 160 / 4.5 and 320 / 9 budesonide & formoterol dry powder inhaler JPC Recommendations
More informationAn assessment of the appropriate use of medicines in older patients with impaired kidney function, in a general practice setting
University of Wollongong Research Online Faculty of Science, Medicine and Health - Papers Faculty of Science, Medicine and Health 015 An assessment of the appropriate use of medicines in older patients
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE July 5, 2016 SUBJECT EFFECTIVE DATE July 11, 2016 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Anticoagulants - Pharmacy Services Leesa M. Allen, Deputy Secretary
More informationProf. Fiorenzo Gaita
Adavances in Cardiac Arrhythmias and Great Innovations in Cardiology Turin 2014 Can rhythm control strategy reduce the risk of clinical and silent cerebral ischemia? Prof. Fiorenzo Gaita Director of the
More informationPharmacists appreciably improving sartan prescribing efficiency in the UK; implications for other classes and countries
Pharmacists appreciably improving sartan prescribing efficiency in the UK; implications for other classes and countries Brian Godman, Andrew Martin, Jeanette Tilstone and Nigget Saleem (KI Sweden and NHS
More informationResponsible Respiratory Prescribing
Responsible Respiratory Prescribing Dr Vincent Mak Consultant Physician in Respiratory Integrated Care Imperial College Healthcare and Central London Community Healthcare NHS Trust NHS England (London)
More informationIdentifying High Greenhouse Gas Intensity Prescription Items for NHS in England. Final Report. February 2014
Identifying High Greenhouse Gas Intensity Prescription Items for NHS in England Final Report February 2014 Delivering sustainable solutions in a more competitive world Sustainable Development Unit Identifying
More informationREGISTRATION ASSESSMENT SITTINGS Part 2 example questions
Notes RGISTRTION SSSSMNT SITTINGS 2018 Part 2 example questions 1. For questions 1-20 there are five options,,,, and. For questions 21-30 there are eight options,,,,,, F, G and H. hoose only one of the
More informationAppendix C Factors to consider when choosing between anticoagulant options and FAQs
Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened
More informationRespiratory Inhalers. Identification Guide Version 3
Respiratory Inhalers Identification Guide Version 3 This booklet has been prepared by NHSGGC Medicines Information. Endorsed by NHSGGC Respiratory Managed Clinical Network, February 2017. Designed by Medical
More informationPRACTICAL MANAGEMENT OF NOAC s December 8,
PRACTICAL MANAGEMENT OF NOAC s December 8, 2017 1 Faculty Disclosure Faculty: John Eikelboom MBBS, MSc, FRCPC Jack Hirsh/PHRI Chair in Thrombosis and Atherosclerosis Career Award, Heart and Stroke Foundation
More informationbeclometasone 100 MDI 2 puffs twice a day (recently changed to non CFC (Clenil Modulite))
Case 1 Mr Thomson, a 32 year old asthmatic who is well known to you comes into your pharmacy. He is known to have a best peak flow of 640 L/min. He tells you that over the last few weeks he has been wakening
More informationWS8 - ADEQUATE PHARMACEUTICAL CARE FOR PATIENTS ON ANTICOAGULATION. ESCP 2017, Heidelberg
WS8 - ADEQUATE PHARMACEUTICAL CARE FOR PATIENTS ON ANTICOAGULATION ESCP 2017, Heidelberg YOUR MODERATORS Bart van den Bemt, The Netherlands Silas Rydant, Belgium Stephane Steurbaut, Belgium Heidelberg,
More informationAdult Summary flowchart for Asthma Switch and Step Down to preferred inhaler choices
HVCCG Adult Asthma Switch and Step Down Algorithms - Approved by Hertfordshire Medicines Management Committee June 2016 Page 1 of 6 Adult Summary flowchart for Asthma Switch and Step Down to preferred
More information2 Summary of NICE TA 249: Atrial fibrillation - Dabigatran Etexilate
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals NICE TA 249: Atrial fibrillation - Dabigatran Etexilate 1 Name of Commissioning Team Long Term Conditions Commissioning Team
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Oral Anticoagulants Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Oral Anticoagulant - Bevyxxa (betrixaban), Eliquis (apixaban), Pradaxa (dabigatran),
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationTHE COPD PRESCRIBING TOOL
THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their
More informationrequesting information regarding Rebate and QIPP prescribing schemes in NHS Canterbury and Coastal Clinical Commissioning Group
July 2015 Our Ref: FOI.15.CAN0059 requesting information regarding Rebate and QIPP prescribing schemes in NHS Canterbury and Coastal Clinical Commissioning Group Could you please provide me with the details
More informationMedicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD) Approved by Prof. Michael Barry, Clinical Lead, MMP. Date approved Version 1 July 2014 Date updated Version
More informationQuestion 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG:
Atrial Fibrillation in Your Area Question 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG: a) What was the prevalence of atrial fibrillation (AF)? 6636 (as of 22/10/2015) 2.1%
More informationStepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs
Step Down guidance Stepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs Important Complete asthma control needs to be achieved for at least 12 weeks before attempting to step patients
More informationLipid Lowering in patients with High Risk of Cardiovascular Disease (Primary Prevention)
Lipid Lowering in patients with High Risk of Cardiovascular Disease (Primary Prevention) Policy Statement: October 2010 This policy defines the decision made by NHS Wirral following an evidence review
More informationMediscor Medicines Review 2011
Mediscor Medicines Review 2011 Mediscor Client Workshop 2012 28 August 2012 Presented by: Madelein Bester Benefit Management Mediscor PBM Content Background of the report Overall trends Expenditure per
More informationMedicines Management Team Update
Medicines Management Team Update Medicines Optimisation in 2017 Deprescribing/reducing variation Care homes Dietetics Improving Clinical outcomes e.g. reducing stroke, Antibiotics Joint Formulary Responses
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationTreatment Options and How They Work
Treatment Options and How They Work Robin Offord Director of Clinical Pharmacy UCL Hospitals NHS Foundation Trust robin.offord@uclh.nhs.uk Introducing the term anticoagulant... What they do Inhibit the
More informationThe first stop for professional medicines advice. Community Pharmacy Oral Anticoagulant Safety Audit
Community Pharmacy Oral Anticoagulant Safety Audit This audit has been developed with help and support from the following organisations: Community Pharmacy Patient Safety Group PharmOutcomes Pharmaceutical
More informationComparison of novel oral anticoagulants (NOACs)
Comparison of novel oral anticoagulants (NOACs) For guidance for full information refer to individual SPCs available at www.medicines.org.uk Licensed indications for NOACs Prevention of stroke and systemic
More informationChapter 3: Respiratory System (7 th Edition)
Chapter 3: Respiratory System (7 th Edition) The Sheffield respiratory guidelines (April 2015) have been removed from the intranet. This is because the COPD section has been superseded by the COPD treatment
More informationThe Impact of Generic Entry on the Utilization of the Ingredient
Patented Medicine Prices Review Board Conseil d examen du prix des médicaments brevetés The Impact of on the Utilization of the Ingredient September 2011 National Prescription Drug Utilization Information
More informationBNF CHAPTER 3: RESPIRATORY
3.1 BRONCHODILATORS BNF CHAPTER 3: RESPIRATORY 3.1.1.1 SELECTIVE BETA 2 -AGONISTS Short acting Salbutamol 100 micrograms/actuation aerosol inhaler 100 micrograms/actuation breath-actuated (e.g., Easi-Breathe
More informationMedicines for stroke prevention in atrial fibrillation. Choosing the right one for you
Medicines for stroke prevention in atrial fibrillation Choosing the right one for you Atrial fibrillation (AF) is a condition that affects the heart, causing it to beat irregularly and too fast. When this
More informationSW Locality PBC Consortium Notes re Prescribing Data
SW Locality PBC Consortium Notes re Prescribing Data Enclosed data is for SW Locality PBC Consortium practices from current 12 months as at Mar 07 Top 50 by cost identified Areas that could achieve quick
More informationWarfarin & You By V. B. Blake
Warfarin & You By V. B. Blake Warfarin is an anticoagulant used to to prevent heart attacks, strokes, and blood clots. Learn about side effects, interactions and indications. Can you tell me what I should
More informationStepping down asthma treatment guidelines
Stepping down asthma treatment guidelines The potential for inhaled corticosteroids (ICS) to cause dose-related side-effects has led to asthma management guidelines recommending a dose reduction once asthma
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist
More informationBlood-thinning medication after stroke
Call the Stroke Helpline: 0303 3033 100 or email: info@stroke.org.uk Blood-thinning medication after stroke Blood-thinning medicines are drugs that help to prevent clots forming in your blood. They are
More informationChapter / Section / Drug
2 Cardiovascular System 2.1 Positive inotropic drugs Digoxin Digoxin specific antibody ( DigiFab ) 2.2 Diuretics 2.2.1 Thiazides and related diuretics Indapamide (1 st Line) Bendroflumethiazide Metolazone
More informationError! No text of specified style in document.
Inhaled corticosteroids and long-acting beta 2 -agonists for the treatment of chronic asthma in children under the age of 12 years: Systematic review and economic analysis Amended cost-off set comparisons
More informationAlgorithm for the use of inhaled therapies in COPD
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationAlgorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
More informationInhalers containing CFCs. CFC-free inhalers
Propellants used in medical metered dose inhalers and aerosol-based breath activated devices in New Zealand August to October 2002 (most recent period for which data is available) (February 2003) Inhalers
More information